901 reports of this reaction
1.6% of all VALPROIC ACID reports
#11 most reported adverse reaction
FOETAL EXPOSURE DURING PREGNANCY is the #11 most commonly reported adverse reaction for VALPROIC ACID, manufactured by Actavis Pharma, Inc.. There are 901 FDA adverse event reports linking VALPROIC ACID to FOETAL EXPOSURE DURING PREGNANCY. This represents approximately 1.6% of all 57,615 adverse event reports for this drug.
VALPROIC ACID has an overall safety score of 92 out of 100. Patients taking VALPROIC ACID who experience foetal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FOETAL EXPOSURE DURING PREGNANCY is a less commonly reported adverse event for VALPROIC ACID, but still significant enough to appear in the safety profile.
In addition to foetal exposure during pregnancy, the following adverse reactions have been reported for VALPROIC ACID:
The following drugs have also been linked to foetal exposure during pregnancy in FDA adverse event reports:
FOETAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 901 FDA reports for VALPROIC ACID. This does not prove causation, but indicates an association observed in post-market surveillance data.
FOETAL EXPOSURE DURING PREGNANCY accounts for approximately 1.6% of all adverse event reports for VALPROIC ACID, making it a notable side effect.
If you experience foetal exposure during pregnancy while taking VALPROIC ACID, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.